Tango Therapeutics (TNGX) Non-Current Deffered Revenue (2020 - 2025)
Historic Non-Current Deffered Revenue for Tango Therapeutics (TNGX) over the last 6 years, with Q2 2025 value amounting to $30.4 million.
- Tango Therapeutics' Non-Current Deffered Revenue fell 4408.97% to $30.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $30.4 million, marking a year-over-year decrease of 4408.97%. This contributed to the annual value of $44.8 million for FY2024, which is 3286.74% down from last year.
- Per Tango Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $30.4 million for Q2 2025, which was down 4408.97% from $37.5 million recorded in Q1 2025.
- In the past 5 years, Tango Therapeutics' Non-Current Deffered Revenue registered a high of $116.6 million during Q3 2021, and its lowest value of $5.8 million during Q1 2021.
- In the last 5 years, Tango Therapeutics' Non-Current Deffered Revenue had a median value of $68.7 million in 2023 and averaged $68.3 million.
- Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first surged by 189869.78% in 2021, then crashed by 4408.97% in 2025.
- Tango Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $114.7 million in 2021, then dropped by 19.73% to $92.1 million in 2022, then dropped by 27.59% to $66.7 million in 2023, then crashed by 32.87% to $44.8 million in 2024, then plummeted by 32.01% to $30.4 million in 2025.
- Its last three reported values are $30.4 million in Q2 2025, $37.5 million for Q1 2025, and $44.8 million during Q4 2024.